ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P5-18 New Medical Drug-Related PA Requirements for Yescarta and Kymriah
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 01, 2018
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 3011 - 3020 လၢ 3273 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P4-18 Changes to Medical Policy IV-126 Sacroiliac Joint Fusion
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 24, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P3-18 New Drug-Related PA Criteria: Inhaled Antibiotics Duplicate Therapy
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 24, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP7-18 Disclosure of Ownership Form
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 18, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP6-18 Updated Commercial PA Request Form and PA List for Early Intensive Behavioral Intervention Services
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 17, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP5-18 Quality Initiatives at Blue Cross
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 16, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP4-18 Remember to Request Subscriber ID Cards
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 16, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P2-18 New Medical Drug PA Requirements for Voretigene Neparvovec (Luxturna)
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 11, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P1-18 New Drugs, Aimovig (erenumab), Fremanezumab and Galcanezumab Will Require PA
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 09, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP3-18 Pharmacy Benefit Update - Helixate FS Will No Longer Be Covered
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 08, 2018